Brucellosis-associated hemophagocytic lymphohistiocytosis: a case report and literature review
Abstract
Introduction: Hemophagocytic lymphohistiocytosis (HLH), a rare and deadly disease, is typically classified as either primary (familial) or secondary (acquired), depending on the etiology and underlying cause. Secondary HLH often develops in the presence of infectious, malignant, rheumatologic, or metabolic conditions, with infections, especially Epstein-Barr virus (EBV) infection, being among the leading causes. Brucella infection-induced HLH is relatively rare, with only eight cases reported in the past decade, all of which had a favorable prognosis following timely diagnosis and treatment.
Case description: A 53-year-old man with brucellosis who developed secondary HLH and multiple organ dysfunction presented to our hospital with a 2-month history of fever and abnormal liver enzymes. Initial blood culture following admission confirmed Brucella spp. in the aerobic bottle after ⁓87.85 h of incubation. However, after the initial discharge, the patient did not adhere to the prescribed antibiotic therapy and subsequently developed symptoms of fever and abdominal discomfort, and was readmitted to our hospital. Laboratory examination also revealed pancytopenia. An additional blood culture further revealed the growth of Brucella spp. in the aerobic bottle after ⁓113.67 h of incubation. Other findings included decreased fibrinogen, increased ferritin, increased soluble IL-2 receptor α chain (sCD25), decreased Natural Killer (NK) cell activity, presence of hemophagocytic cells in…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.